Name: A Novel Feeder-free System for Mass Production of Murine Natural Killer Cells In Vitro (Video) | JoVE Journal
Uploaded: 2018-01-09T14:00:00.000+00:00
Duration: 10 min 36 s
Description: Learn a feeder-free method to mass produce high-purity murine natural killer cells from bone marrow for innate immunology and cancer immunity research. This protocol enables gene silencing studies and in vivo applications.

ai_agent_IP

ai_agent

maintenance

instantTrialDurationMinutes

isBiopharma

enableNewMyJoveSectionDesign

educationFeatures

seoMetaApi

ai_copilot_institution_blacklist

ai_chat_institution_blacklist

freeAccessWindow

ssoRoleCapture

scheduledMaintenanceBanner

joveLabsFeatures

disable_autoplay_for_bots

extended_trial_duration

5 minutes

This study was supported by the Research Grants Council of Hong Kong (GRF 468513, CUHK3/CRF/12R) and the Innovation and Technology Fund of Hong Kong (ITS/227/15, ITS InP/164/16, ITS-InP/242/16), Direct Grant for Research-CUHK (2016.035), and Hong Kong Scholar Program.
H.-Y.L. designed and supervised all experiments and contributed to manuscript preparation. P.M.-K.T. performed experiments, analyzed data and contributed to manuscript preparation. P.C.-T. T., J.Y.-F.C., J.S.-C.,H., Q.-M.W., and G.-Y.L. collected animal samples and participated in animal experiments. J.S., X.-R.H., and K.-F.T. contributed to manuscript preparation.

The protocol for obtaining and differentiating bone marrow-derived NK cells (BM-NK) is based on previously published methods20,21,22. All procedures with mice have been approved by the Animal Ethics Experimental Committee (AEEC) at the Chinese University of Hong Kong.
1. Preparation of OP9 Conditional Medium
<ol>
	<li>Culture the murine stroma cell line OP9 in alpha-MEM containing 20% FBS, 100 U/mL penicillin G and 100 &#181;g/mL streptomycin, at 37 &#176;C in a humidified atmosphere of air/CO2 (95%:5%).
	<ol>
		<li>Count the cells with a hemocytometer, then seed 2 x 106 of OP9 cells to each 75 cm2 culture flask with 15 mL of medium. Culture for 48 h.</li>
		<li>When the culture reaches 80% confluence, wash the flask with 10 mL of PBS and add 20 mL of plain alpha-MEM medium (without FBS and antibiotics) per flask.</li>
	</ol>
	</li>
	<li>Collect the OP9 condition medium from the culture flask at 24 h, clean up cell debris with 0.25 &#181;m polyethersulfone (PES) filter and preserve at 4 &#176;C (use within 2 weeks).</li>
</ol>
2. Isolation of Mouse Bone Marrow Cells
<ol>
	<li>Euthanize a 12-week-old C57BL/6J mouse with a pentobarbitone overdose (100 mg/kg, intraperitoneal injection). Confirm death by the lack of breathing, then harvest the femur bones with a surgical knife cutting at the junctions between bones and remove the remaining muscles with the blade by gentle scratching.</li>
	<li>Place the bones in a 50 mL centrifuge tube containing chilled sterile alpha-MEM, and then perform the following steps in a biosafety cabinet.</li>
	<li>Discard the alpha-MEM medium, and rinse the bones with 70% ethanol for 30 s.</li>
	<li>Wash the bones with ice-cold sterile PBS twice to clean up the remaining ethanol.</li>
	<li>Transfer the bones in a mortar containing 5 mL of ice-cold PBS, and gently fragmentize the bones with a pestle (do not pulverize them).</li>
	<li>Agitate the bones gently by swirling the pestle to release the bone marrow cells into the PBS. Collect the PBS containing bone marrow cells into a new 50 mL centrifuge tube.</li>
	<li>Repeat step 2.6 for four times until the bone fragments become solid white in color.</li>
	<li>Centrifuge the tube at 465 x g for 5 min at 4 &#176;C, then discard the supernatant.</li>
	<li>Resuspend the pellet with 18 mL of sterile distilled water and let it stand for 30 s to remove red blood cells.</li>
	<li>Add 2 mL of ice-cold 10X PBS to stop the reaction, then filter the mixture through a 70 &#181;m cell strainer to remove the lysed red blood cells.</li>
	<li>Centrifuge the tube at 465 x g for 5 min at 4 &#176;C. Resuspend the pellet with 20 mL of ice-cold PBS.</li>
	<li>Wash the cells by repeating step 2.11 a second time.</li>
	<li>Transfer the cell pellet into a 100-mm sterile Petri dish with 10 mL of OP9 conditional medium from step 1.2 supplemented with 20% FBS and a mixture of 0.5 ng/mL murine IL-7, 30 ng/mL mouse SCF, and 100 U/mL murine flt3L.</li>
	<li>Incubate the dish at 37 &#176;C with 5% CO2 for 2 h. Transfer the unattached cells into a new culture container at a density of 5 x 105 viable cells/mL (count cells by hemocytometer with trypan-blue exclusion) with the same medium formula as in step 2.13, and incubate at 37 &#176;C with 5% CO2.</li>
	<li>On day 4, change the culture condition to OP9 conditional medium supplemented with 20% FBS and 2,000 U/mL of murine IL-2.</li>
	<li>Refresh the culture medium every 3 days; mature NK cells can be obtained by Day 7 and qualified as in section 4.</li>
</ol>
3. siRNA-mediated Gene Silencing of Differentiating NK Cells
<ol>
	<li>Premix the siRNA or nonsense control (NC) with a transfection agent according to the product manual.</li>
	<li>Perform step 3.1 at any time point since day 0.</li>
	<li>Add the 50 nM of siRNA or NC mixture to the cells from step 2.14.</li>
	<li>Repeat step 3.1 on every medium refreshment (e.g., Day 0, 4, and 7) until the experimental end point.</li>
</ol>
4. Analysis of NK Cell Differentiation Using Flow Cytometry
<ol>
	<li>At an appropriate time point, collect the suspension of differentiating cells and wash with ice-cold PBS.</li>
	<li>Fix the cells with cell fixation buffer according to the product manual.</li>
	<li>Wash the fixed cells with ice-cold PBS, and then resuspend 1 x 106 cells in 100 &#181;L of Flow Cytometry Staining Buffer containing Cy3-conjugated anti-mouse NKp46 and PE-conjugated anti-mouse CD244 antibodies in a dilution ratio of 1:100.</li>
	<li>Stain the sample in the dark at room temperature for 2 h.</li>
	<li>Resuspend the stained samples with 300 &#181;L of PBS, then acquire FACS data and analyze with Cytobank platform20 (http://cytobank.org/).</li>
</ol>

<ol><li>Schreiber, R. D., Old, L. J., Smyth, M. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Cancer+immunoediting%3A+integrating+immunity%27s+roles+in+cancer+suppression+and+promotion%5BTitle%5D)+AND+%22Science%22%5BJournal%5D)">Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion.</a> Science. 331 (6024), 1565-1570 (2011).</li>
<li>Junttila, M. R., de Sauvage, F. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Influence+of+tumour+micro-environment+heterogeneity+on+therapeutic+response%5BTitle%5D)+AND+%22Nature%22%5BJournal%5D)">Influence of tumour micro-environment heterogeneity on therapeutic response.</a> Nature. 501 (7467), 346-354 (2013).</li>
<li>Rusakiewicz, S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Immune+infiltrates+are+prognostic+factors+in+localized+gastrointestinal+stromal+tumors%5BTitle%5D)+AND+%22Cancer+Res%22%5BJournal%5D)">Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors.</a> Cancer Res. 73 (12), 3499-3510 (2013).</li>
<li>Mamessier, E., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Human+breast+cancer+cells+enhance+self+tolerance+by+promoting+evasion+from+NK+cell+antitumor+immunity%5BTitle%5D)+AND+%22J+Clin+Invest%22%5BJournal%5D)">Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity.</a> J Clin Invest. 121 (9), 3609-3622 (2011).</li>
<li>Stern, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Pre-emptive+immunotherapy+with+purified+natural+killer+cells+after+haploidentical+SCT%3A+a+prospective+phase+II+study+in+two+centers%5BTitle%5D)+AND+%22Bone+Marrow+Transplant%22%5BJournal%5D)">Pre-emptive immunotherapy with purified natural killer cells after haploidentical SCT: a prospective phase II study in two centers.</a> Bone Marrow Transplant. 48 (3), 433-438 (2013).</li>
<li>Miller, J. S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Successful+adoptive+transfer+and+in+vivo+expansion+of+human+haploidentical+NK+cells+in+patients+with+cancer%5BTitle%5D)+AND+%22Blood%22%5BJournal%5D)">Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer.</a> Blood. 105 (8), 3051-3057 (2005).</li>
<li>Rubnitz, J. E., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((NKAML%3A+a+pilot+study+to+determine+the+safety+and+feasibility+of+haploidentical+natural+killer+cell+transplantation+in+childhood+acute+myeloid+leukemia%5BTitle%5D)+AND+%22J+Clin+Oncol%22%5BJournal%5D)">NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia.</a> J Clin Oncol. 28 (6), 955-959 (2010).</li>
<li>Curti, A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Successful+transfer+of+alloreactive+haploidentical+KIR+ligand-mismatched+natural+killer+cells+after+infusion+in+elderly+high+risk+acute+myeloid+leukemia+patients%5BTitle%5D)+AND+%22Blood%22%5BJournal%5D)">Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients.</a> Blood. 118 (12), 3273-3279 (2011).</li>
<li>Bachanova, V., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Clearance+of+acute+myeloid+leukemia+by+haploidentical+natural+killer+cells+is+improved+using+IL-2+diphtheria+toxin+fusion+protein%5BTitle%5D)+AND+%22Blood%22%5BJournal%5D)">Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein.</a> Blood. 123 (25), 3855-3863 (2014).</li>
<li>Stringaris, K., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Leukemia-induced+phenotypic+and+functional+defects+in+natural+killer+cells+predict+failure+to+achieve+remission+in+acute+myeloid+leukemia%5BTitle%5D)+AND+%22Haematologica%22%5BJournal%5D)">Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia.</a> Haematologica. 99 (5), 836-847 (2014).</li>
<li>Rouce, R. H., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((The+TGF-%CE%B2%2FSMAD+pathway+is+an+important+mechanism+for+NK+cell+immune+evasion+in+childhood+B-acute+lymphoblastic+leukemia%5BTitle%5D)+AND+%22Leukemia%22%5BJournal%5D)">The TGF-β/SMAD pathway is an important mechanism for NK cell immune evasion in childhood B-acute lymphoblastic leukemia.</a> Leukemia. 30 (4), 800-811 (2016).</li>
<li>Derynck, R., Akhurst, R. J., Balmain, A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((TGF-%CE%B2+signaling+in+tumor+suppression+and+cancer+progression%5BTitle%5D)+AND+%22Nature+Genet%22%5BJournal%5D)">TGF-β signaling in tumor suppression and cancer progression.</a> Nature Genet. 29 (2), 117-129 (2001).</li>
<li>Massague, J. <a target="_blank" href="https://www.ncbi.nlm.nih.gov/pubmed/18662538">TGFbeta in cancer.</a> Cell. 134 (2), 215-230 (2008).</li>
<li>Ikushima, H., Miyazono, K. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((TGFbeta+signalling%3A+a+complex+web+in+cancer+progression%5BTitle%5D)+AND+%22Nat+Rev+Cancer%22%5BJournal%5D)">TGFbeta signalling: a complex web in cancer progression.</a> Nat Rev Cancer. 10 (6), 415-424 (2010).</li>
<li>Pickup, M., Novitskiy, S., Moses, H. L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((The+roles+of+TGF%CE%B2+in+the+tumour+microenvironment%5BTitle%5D)+AND+%22Nat+Rev+Cancer%22%5BJournal%5D)">The roles of TGFβ in the tumour microenvironment.</a> Nat Rev Cancer. 13 (11), 788-799 (2013).</li>
<li>Rook, A. H., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Effects+of+transforming+growth+factor+beta+on+the+functions+of+natural+killer+cells%3A+depressed+cytolytic+activity+and+blunting+of+interferon+responsiveness%5BTitle%5D)+AND+%22J+Immunol%22%5BJournal%5D)">Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness.</a> J Immunol. 136 (10), 3916-3920 (1986).</li>
<li>Bellone, G., Aste-Amezaga, M., Trinchieri, G., Rodeck, U. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Regulation+of+NK+cell+functions+by+TGF-beta+1%5BTitle%5D)+AND+%22J+Immunol%22%5BJournal%5D)">Regulation of NK cell functions by TGF-beta 1.</a> J Immunol. 155 (3), 1066-1073 (1995).</li>
<li>Trotta, R., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((TGF-%CE%B2+utilizes+SMAD3+to+inhibit+CD16-mediated+IFN-%CE%B3+production+and+antibody-dependent+cellular+cytotoxicity+in+human+NK+cells%5BTitle%5D)+AND+%22J+Immunol%22%5BJournal%5D)">TGF-β utilizes SMAD3 to inhibit CD16-mediated IFN-γ production and antibody-dependent cellular cytotoxicity in human NK cells.</a> J Immunol. 181 (6), 3784-3792 (2008).</li>
<li>Shull, M. M., et al. <a target="_blank" href="https://www.ncbi.nlm.nih.gov/pubmed/1436033">Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease.</a> Nature. 359 (6397), 693-699 (1992).</li>
<li>Chen, T. J., Kotecha, N. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Cytobank%3A+providing+an+analytics+platform+for+community+cytometry+data+analysis+and+collaboration%5BTitle%5D)+AND+%22Curr+Top+Microbiol+Immunol%22%5BJournal%5D)">Cytobank: providing an analytics platform for community cytometry data analysis and collaboration.</a> Curr Top Microbiol Immunol. 377, 127-157 (2014).</li>
<li>Williams, N. S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Differentiation+of+NK1.1%2B%2C+Ly49%2B+NK+cells+from+flt3%2B+multipotent+marrow+progenitor+cells%5BTitle%5D)+AND+%22J+Immunol%22%5BJournal%5D)">Differentiation of NK1.1+, Ly49+ NK cells from flt3+ multipotent marrow progenitor cells.</a> J Immunol. 163 (5), 2648-2656 (1999).</li>
<li>Fathman, J. W., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Identification+of+the+earliest+natural+killer+cell-committed+progenitor+in+murine+bone+marrow%5BTitle%5D)+AND+%22Blood%22%5BJournal%5D)">Identification of the earliest natural killer cell-committed progenitor in murine bone marrow.</a> Blood. 118 (20), 5439-5447 (2011).</li>
<li>Tang, P. M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Smad3+promotes+cancer+progression+by+inhibiting+E4BP4-mediated+NK+cell+development%5BTitle%5D)+AND+%22Nat+Commun%22%5BJournal%5D)">Smad3 promotes cancer progression by inhibiting E4BP4-mediated NK cell development.</a> Nat Commun. 6 (8), 14677(2017).</li>
</ol>

The authors have nothing to disclose.

In the present work, we have described a novel method for producing bone marrow-derived murine NK cells in vitro. The cell feeder in the original system21,22 is successfully replaced by the conditional medium of OP9 cells, which largely increased the stability of the differentiation system. In addition, the system can produce high quantity and purity of mature NK cells for in vitro as well as in vivo assays, which can facilitate the mec...

Cancer progression is largely dependent on the tumor microenvironment1,2, including host-derived immunocytes, e.g., NK cells. Several studies demonstrated that intratumoral NK cells are negatively correlated with the tumor progression3,4. In addition, clinical studies showed that NK cell adoptive therapy is a possible strategy for cancer5,6,7,8,9. NK cell-based cancer immunotherapy was recently suggested as a therapeutic option for solid tumors, but challenges exist due to the secretion of immunosuppressive cytokines and downregulation of activating ligands in the microenvironment of solid tumors10,11. Transforming growth factor-&#946; (TGF-&#946;) has been suggested to play a suppressive role in carcinogenesis, but paradoxically cancer cells also produce TGF-&#946;1 to support the tumor development12,13,14,15. TGF-&#946; signaling can suppress the cytolytic activity of NK cells via down-regulating interferon responsiveness and CD16-mediated interferon-gamma (IFN-&#947;) production in vitro16,17,18.
Although disruption of TGF-&#946; signaling in the tumor microenvironment may be a possible way for eliminating cancers, completely blocking TGF-&#946; signaling will cause autoimmune diseases due to its anti-inflammatory function, as evidenced by the development of adverse side effects including systemic inflammation, cardiovascular defects, and autoimmunity in mouse models19. Thus, understanding the working mechanism of TGF-&#946;-mediated immunosuppression will lead to the identification of an accessible therapeutic target for treating cancer.
To elucidate the molecular events necessary for NK cell development, Williams et al. established an in vitro system for differentiating murine bone marrow hematopoietic stem cells into NK cells20. This system largely facilitates the mechanistic study of NK cell development, including the identification of novel progenitors of NK cells21. However, the bone marrow progenitors should be cultured in the system with supporting OP9 stromal cells as a feeder layer20,21, and this heterogeneous cell population largely limits the further application of gene-disrupting tools (e.g., siRNA-mediated gene silencing) specifically applied to the differentiating NK cells.
Here, we describe a feeder-free system that has been developed by further modifying the in vitro system of Williams et al20. In our system, the OP9 stromal feeder cells are not required, and instead OP9 conditional medium is used without affecting the differentiation of NK cells in vitro, and this recently lead us to uncover that TGF-&#946; is able to promote cancer progression via suppressing E4bp4-dependent NK cell development in the tumor microenvironment22. This novel system successfully provides a background-free method for elucidating the molecular mechanism of NK cell development under specific conditions (e.g., high TGF- &#946;1, siRNA-mediated gene silencing, etc.) in vitro.

<table><tbody><tr><td>OP9 cell line</td><td>ATCC</td><td>ATCC&lt;sup&gt;&amp;reg;&lt;/sup&gt; CRL-2749&lt;sup&gt;&amp;trade;&lt;/sup&gt;</td><td></td></tr><tr><td>MEM &amp;alpha;, no nucleosides</td><td>Gibco</td><td>22561021</td><td></td></tr><tr><td>Fetal Bovine Serum</td><td>Gibco</td><td>10500064</td><td></td></tr><tr><td>PBS, pH 7.4</td><td>Gibco</td><td>10010049</td><td></td></tr><tr><td>Recombinant Murine IL-7</td><td>PEPROTECH</td><td>217-17</td><td></td></tr><tr><td>Recombinant Murine SCF</td><td>PEPROTECH</td><td>250-03</td><td></td></tr><tr><td>Recombinant Murine Flt3-Ligand</td><td>PEPROTECH</td><td>250-31L</td><td></td></tr><tr><td>Recombinant Murine IL-2</td><td>PEPROTECH</td><td>212-12</td><td></td></tr><tr><td>Lipofectamin RNAiMAX Transfection Reagent</td><td>Invitrogen</td><td>1377815</td><td></td></tr><tr><td>IC Fixation Buffer&amp;nbsp;</td><td>eBioscience</td><td>00-8222-49</td><td></td></tr><tr><td>Flow Cytometry Staining Buffer&amp;nbsp;</td><td>eBioscience</td><td>00-4222-26</td><td></td></tr><tr><td>PE-conjugated anti-mouse CD244</td><td>eBioscience</td><td>12-2441-83</td><td></td></tr><tr><td>Cy3-conjugated anti-mouse NKp46</td><td>Bioss</td><td>bs-2417R-cy3</td><td></td></tr><tr><td>Nonsense control (NC)</td><td>Ribobio</td><td>siN05815122147</td><td></td></tr><tr><td>siRNA against mouse E4BP4 mRNA</td><td>Ribobio</td><td>N/A</td><td>5&amp;prime;-GAUGAGGGUGUA&lt;br/&gt; GUGGGCAAGUCUU-3&amp;prime;</td></tr></tbody></table>

a novel feeder-free system for mass production of murine natural killer cells in vitro

A Novel Feeder-free System for Mass Production of Murine Natural Killer Cells In Vitro

Natural killer (NK) cells belong to the innate immune system and are a first-line anti-cancer immune defense; however, they are suppressed in the tumor microenvironment and the underlying mechanism is still largely unknown. The lack of a consistent and reliable source of NK cells limits the research progress of NK cell immunity. Here, we report an in vitro system that can provide high quality and quantity of bone marrow-derived murine NK cells under a feeder-free condition. More importantly, we also demonstrate that siRNA-mediated gene silencing successfully inhibits the E4bp4-dependent NK cell maturation by using this system. Thus, this novel in vitro NK cell differentiating system is a biomaterial solution for immunity research.

Representative results are obtained following the described protocol. Total bone marrow suspension cells were cultivated under the feeder-free differentiation system for 11 days; significant increase in proliferation rate was observed by day 7 compared with the number of total cells on day 0 (Figure 1A). Mature NK cells with high nuclear to cytoplasmic ratio and granule-rich cytoplasm morphology were found by day 6 in the system (<strong clas...

Here, we present a protocol to mass-produce gene-silencing murine NK cells by using a feeder-free differentiation system for mechanistic study in vitro and in vivo.

Natural killer (NK) cells belong to the innate immune system and are a first-line anti-cancer immune defense; however, they are suppressed in the tumor ...

a-novel-feeder-free-system-for-mass-production-murine-natural-killer

Research

JoVE Journal

Immunology and Infection

Here we describe a method to efficiently expand and purify large numbers of human NK cells and assess their function.

Expansion, Purification, and Functional Assessment of Human Peripheral Blood NK Cells 

This video demonstrates a technique for the expansion of natural killer (NK) cells directly from peripheral blood mononuclear cells (PBMCs) using a feeder cell line. PBMCs are co-cultured with genetically modified lymphoblastoid feeder cells expressing membrane-bound interleukin-21 (mIL-21), and the culture is supplemented with the cytokines interleukin-2 (IL-2) and interleukin-15 (IL-15). Together, this cocktail of ligands leads to the prolonged expansion of NK cells with high purity.

Ex Vivo Expansion of Natural Killer Cells from Peripheral Blood Mononuclear Cells

This protocol describes the development, expansion, and in vivo imaging of NK cells derived from hESCs and iPSCs.

Development, Expansion, and In vivo Monitoring of Human NK Cells from Human Embryonic Stem Cells (hESCs) and Induced Pluripotent Stem Cells (iPSCs)

In this study we present an in vitro culture system that can efficiently generate pDCs by co-culturing common lymphoid progenitors with AC-6 feeder cells in the presence of Flt3 ligand.

In Vitro Generation of Murine Plasmacytoid Dendritic Cells from Common Lymphoid Progenitors using the AC-6 Feeder System

Here we present an adapted protocol that can be used to generate a large number of murine invariant natural killer T cells from mouse spleen. The protocol outlines an approach by which splenic iNKT cells can be enriched for, isolated and expanded in vitro using a limited number of animals and reagents.

An Optimized Method for Isolating and Expanding Invariant Natural Killer T Cells from Mouse Spleen

We describe a rapid and robust protocol to enrich invariant natural killer T (iNKT) cells from mouse spleen and expand them in vitro to suitable numbers for in vitro and in vivo studies.

Purification and Expansion of Mouse Invariant Natural Killer T Cells for in vitro and in vivo Studies

Here, we present a method to expand peripheral blood natural killer (PBNK), NK cells from liver tissues, and chimeric antigen receptor (CAR)-NK cells derived from peripheral blood mononuclear cells (PBMCs) or cord blood (CB). This protocol demonstrates the expansion of NK and CAR-NK cells using 221-mIL-21 feeder cells in addition to the optimized purity of expanded NK cells.

Natural Killer (NK) and CAR-NK Cell Expansion Method using Membrane Bound-IL-21-Modified B Cell Line

The present protocol shows how to differentiate CD3−/CD45+CD56+ cells with mild cytotoxicity from human expanded potential stem cells (hEPSCs) under both 3D and 2D culture conditions. This allows for routine phenotypical validation without the destruction of the complex microenvironment.

Generation of Natural Killer Cells from Human Expanded Potential Stem Cells

Natural killer cell-derived extracellular vesicles (NK-EVs) hold promising potential as cancer biotherapeutics. This methodology-based study presents a scalable closed-loop biomanufacturing workflow designed to continuously produce and isolate large quantities of high-purity NK-EVs. In-process control testing is performed throughout the biomanufacturing workflow, ensuring the EVs meet quality standards for product release.

Scalable Biomanufacturing Workflow to Produce and Isolate Natural Killer Cell-Derived Extracellular Vesicle-Based Cancer Biotherapeutics

This protocol describes a scalable method for the expansion of Adoptive Cell Therapies (ACT) products, namely Chimeric Antigen Receptor (CAR)-T cells and Cytokine-Induced Killer (CIK) cells, using Gas-permeable Rapid expansion (G-Rex) devices, demonstrating efficient and robust growth in a clinically relevant setting.

Efficient and Rapid Generation of CAR-T and Cytokine-Induced Killer Cells in GMP-scalable Devices

Learn a feeder-free method to mass produce high-purity murine natural killer cells from bone marrow for innate immunology and cancer immunity research. This protocol enables gene silencing studies and in vivo applications.

A Novel Feeder-free System for Mass Production of Murine Natural Killer Cells In Vitro

Explore More Videos